Home>>Signaling Pathways>> Obesity, Appetite Control & Diabetes>> Obesity>>trans-Vaccenic Acid-d13

trans-Vaccenic Acid-d13 (Synonyms: C18:1(11E)-d13, C18:1 n-7-d13, trans-11-Octadecenoic Acid-d13)

Catalog No.GC48196

A neuropeptide with diverse biological activities

Products are for research use only. Not for human use. We do not sell to patients.

trans-Vaccenic Acid-d13 Chemical Structure

Cas No.: N/A

Size Price Stock Qty
1 mg
$60.00
In stock
5 mg
$271.00
In stock
10 mg
$479.00
In stock
25 mg
$1,051.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description of trans-Vaccenic Acid-d13

trans-Vaccenic acid-d13 is intended for use an internal standard for the quantification of trans-vaccenic acid by GC- or LC-MS. trans-Vaccenic acid is an ω-7 fatty acid that has been found in bovine milk fats.1 Dietary administration of trans-vaccenic acid (1% w/w) reduces total body fat, mesenteric fat, and adipocyte size, increases inguinal fat mass, and decreases intestinal and hepatic triglyceride secretion in a rat model of obesity with features of metabolic syndrome.2 It decreases hepatocellular ballooning and steatosis, markers of non-alcoholic fatty liver disease (NAFLD), in the same model. Dietary administration of a butter enriched with trans-vaccenic acid decreases serum cholesterol levels and the formation of aortic atherosclerotic lesions in Ldlr-/- mice.3

1.Santora, J.E., Palmquist, D.L., and Roehrig, K.L.Trans-vaccenic acid is desaturated to conjugated linoleic acid in miceJ. Nutr.130(2)208-215(2000) 2.Jacome-Sosa, M.M., Borthwick, F., Mangat, R., et al.Diets enriched in trans-11 vaccenic acid alleviate ectopic lipid accumulation in a rat model of NAFLD and metabolic syndromeJ. Nutr. Biochem.25(7)692-701(2014) 3.Bassett, C.M., Edel, A.L., Patenaude, A.F., et al.Dietary vaccenic acid has antiatherogenic effects in LDLr-/- miceJ. Nutr.140(1)18-24(2010)

Chemical Properties of trans-Vaccenic Acid-d13

Cas No. N/A SDF
Synonyms C18:1(11E)-d13, C18:1 n-7-d13, trans-11-Octadecenoic Acid-d13
Canonical SMILES OC(CCCCCCCCC/C=C/C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])(C([2H])([2H])[2H])[2H])=O
Formula C18H21D13O2 M.Wt 295.5
Solubility DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 100 mg/ml,Ethanol:PBS (pH 7.2): 0.5 mg/ml Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of trans-Vaccenic Acid-d13

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 3.3841 mL 16.9205 mL 33.8409 mL
5 mM 0.6768 mL 3.3841 mL 6.7682 mL
10 mM 0.3384 mL 1.692 mL 3.3841 mL
  • Molarity Calculator

  • Dilution Calculator

  • Molecular Weight Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution) of trans-Vaccenic Acid-d13

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

Reviews

Review for trans-Vaccenic Acid-d13

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for trans-Vaccenic Acid-d13

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.